Please assess the completion status of the following clinical trial:

Trial Title: Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* at least 18 years of age~* corneal transplant recipient with intraocular pressure (IOP) greater than 24 mmHg and with relative increase in IOP of at least 10 mmHg over the pre-graft baseline~Exclusion Criteria:~* not pregnant or lactating~* intraocular surgery in the study eye within 30 days before enrolling in the study~* use of any investigational drug or treatment within 30 days before receipt of study medication~* clinical evidence of scleral thinning

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 30 mg anecortave acetate (Type: ACTIVE_COMPARATOR): None
- 15 mg anecortave acetate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).